Ensign Peak Advisors’s Enanta Pharmaceuticals ENTA Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-20,250
| Closed | -$226K | – | 1746 |
|
|
2023
Q3 | $226K | Buy |
20,250
+4,800
| +31% | +$53.6K | ﹤0.01% | 1721 |
|
|
2023
Q2 | $331K | Hold |
15,450
| – | – | ﹤0.01% | 1705 |
|
|
2023
Q1 | $625K | Buy |
15,450
+250
| +2% | +$10.1K | ﹤0.01% | 1568 |
|
|
2022
Q4 | $707K | Sell |
15,200
-20,070
| -57% | -$934K | ﹤0.01% | 1445 |
|
|
2022
Q3 | $1.83M | Buy |
35,270
+1,186
| +3% | +$61.5K | ﹤0.01% | 815 |
|
|
2022
Q2 | $1.61M | Sell |
34,084
-4,011
| -11% | -$190K | ﹤0.01% | 895 |
|
|
2022
Q1 | $2.71M | Hold |
38,095
| – | – | 0.01% | 769 |
|
|
2021
Q4 | $2.85M | Buy |
38,095
+17,195
| +82% | +$1.29M | 0.01% | 835 |
|
|
2021
Q3 | $1.19M | Hold |
20,900
| – | – | ﹤0.01% | 1370 |
|
|
2021
Q2 | $920K | Buy |
20,900
+500
| +2% | +$22K | ﹤0.01% | 1463 |
|
|
2021
Q1 | $1.01M | Buy |
20,400
+3,500
| +21% | +$173K | ﹤0.01% | 1425 |
|
|
2020
Q4 | $711K | Hold |
16,900
| – | – | ﹤0.01% | 1518 |
|
|
2020
Q3 | $774K | Hold |
16,900
| – | – | ﹤0.01% | 1414 |
|
|
2020
Q2 | $849K | Hold |
16,900
| – | – | ﹤0.01% | 1329 |
|
|
2020
Q1 | $869K | Buy |
16,900
+2,000
| +13% | +$103K | ﹤0.01% | 1223 |
|
|
2019
Q4 | $921K | Buy |
+14,900
| New | +$921K | ﹤0.01% | 1362 |
|